About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.

This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.

Venue Information

The Union League of Philadelphia
140 South Broad Street
Philadelphia, PA 19102
Tel: (215) 405-9578

Add to your Calendar

Past Sponsors


Past Supporters


Who Should Attend


The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • CDER outlines management of breakthrough therapiesFDA's Center for Drug Evaluation and Research published a Manual of Policies and Procedures outlining CDER actions from the time a product receives breakthrough therapy designation until a marketing application has been submitted. According to the manual, CDER should review the status of breakthrough therapy programs every three to six months, and may consider rescinding the designation if the criteria for a breakthrough therapy are no longer met.

Read more

Industry News from PharmAsia

  • Emerging Markets Earnings Roundup: Bristol Myers Squibb (Part 6)Bristol Myers Squibb saw some turbulence for Baraclude sales in China and Japan, but noted Yervoy sales lifted and the company has high hopes for a deal with Ono and its Opdivo oncology treatment.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/AODg_pPHTno" height="1" width="1" />

Read more